BioLamina can support scientists throughout their cell therapy development process– from concept to commercialized therapy. Our Biolaminin® substrates are defined, full-length laminin matrices that can be used for a variety of applications, like the expansion of human pluripotent stem cells and differentiation and maintenance of different specialized cell types, such as hepatocytes, cardiomyocytes, and neural cells. The biologically relevant cell-matrix interaction gives more consistent cellular responses, more standardized experiments, improve the differentiation potential, and keep adult cells mature for a significantly longer time in culture than has previously been feasible. Our Biosilk® 521 product is a new 3D biomaterial made of silk and Biolaminin that allows engineered, controllable, and tunable organoids. BioLamina is a Swedish biotechnology company with a global presence and our laminin technology has been scientifically validated in many high impact journals.